TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07720375: A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

Sponsor: UCB Biopharma SRL · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 300 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT07720375 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07720375 Rescue Dossier →